Search Results - Hulstrom, John

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Contextual Bible Study Notes on John 14:8-18 (25-27) Gospel Reading for Pentecost

    Contextual Bible Study Notes on John 14:8-18 (25-27) Gospel Reading for Pentecost by Hulstrom, John, Ball, Helen, Jones, Russell

    Published in Expository times
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Worship Resources: Contextual Bible Study Notes for July Lectionary Readings

    Worship Resources: Contextual Bible Study Notes for July Lectionary Readings by Jones, Russell, Ball, Helen, Howison, Jacqui, Hulstrom, John

    Published in Expository times
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

    Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial by Schwarz, Tino F, Hwang, Shinn-Jang, Ylisastigui, Pedro, Liu, Chiu-Shong, Takazawa, Kenji, Yono, Makoto, Ervin, John E, Andrews, Charles P, Fogarty, Charles, Eckermann, Tamara, Collete, Delphine, de Heusch, Magali, De Schrevel, Nathalie, Salaun, Bruno, Lambert, Axel, Maréchal, Céline, Olivier, Aurélie, Nakanwagi, Phoebe, Lievens, Marc, Hulstrøm, Veronica

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age

    The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years... by Curran, Desmond, Matthews, Sean, Cabrera, Eliazar Sabater, Pérez, Silvia Narejos, Breva, Lina Pérez, Rämet, Mika, Helman, Laura, Park, Dae Won, Schwarz, Tino F., Melendez, Isabel Maria Galan, Schaefer, Axel, Roy, Nathalie, Stephan, Brigitte, Molnar, Daniel, Kostanyan, Lusine, Powers, John H., Hulstrøm, Veronica

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

    Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial by Schwarz, Tino F, Hwang, Shinn-Jang, Ylisastigui, Pedro, Liu, Chiu-Shong, Takazawa, Kenji, Yono, Makoto, Ervin, John E, Andrews, Charles P, Fogarty, Charles, Eckermann, Tamara, Collete, Delphine, de Heusch, Magali, De Schrevel, Nathalie, Salaun, Bruno, Lambert, Axel, Maréchal, Céline, Olivier, Aurélie, Nakanwagi, Phoebe, Lievens, Marc, Hulstrøm, Veronica

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial

    Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial by F Schwarz, Tino, Hwang, Shinn-Jang, Ylisastigui, Pedro, Liu, Chiu-Shong, Takazawa, Kenji, Yono, Makoto, Ervin, John E, Andrews, Charles P, Fogarty, Charles, Eckermann, Tamara, Collete, Delphine, de Heusch, Magali, De Schrevel, Nathalie, Salaun, Bruno, Lambert, Axel, Maréchal, Céline, Olivier, Aurélie, Nakanwagi, Phoebe, Lievens, Marc, Hulstrøm, Veronica

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination

    119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis a... by Schwarz, Tino F, Hwang, Shinn-Jang, Ylisastigui, Pedro P, Liu, Chiu-Shong, Takazawa, Kenji, Yono, Makoto, Ervin, John E, Andrews, Charles, Fogarty, Charles, Eckermann, Tamara, Vicco, Miguel, Lievens, Marc, Maréchal, Céline, Nakanwagi, Phoebe, Hulstrøm, Veronica

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

    96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at... by Schwarz, Tino F, Hwang, Shinn-Jang, Ylisastigui, Pedro P, Liu, Chiu-Shong, Takazawa, Kenji, Yono, Makoto, Ervin, John E, Andrews, Charles, Fogarty, Charles, Eckermann, Tamara, Collete, Delphine, de Heusch, Magali, Schrevel, Nathalie De, Salaun, Bruno, Lievens, Marc, Maréchal, Céline, Nakanwagi, Phoebe, Hulstrøm, Veronica

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: